DigestRedComo funciona
Red
/
Empresas
Ot
No verificado

Otsuka Pharmaceutical Co., Ltd.

Sobre qué escribimos

BiotecnologíaFarmacéuticaIndustriaMedicina - VariosSalud

23 Comunicados de prensa

Ver todos los comunicados de prensa
22/09/2026
Industria
Salud
Higiene alimentaria
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Otsuka Announces Transformative Phase 3 FUSION Results for Ulefnersen, Bringing the FUS-ALS Community Closer to a Potential Targeted Treatment
Fuente
Otsuka Pharmaceutical Co., Ltd.
Editor
Business Wire
1.00
0
19/09/2026
Ciencia
Biotecnología
Farmacéutica
Salud
Psiquiatría
Medicina - Varios
Industria
Otsuka Presents New Phase 3b Results for SIMTRIYO® (centanafadine) Highlighting Consistent Improvements Across ADHD Symptoms, Anxiety, and Associated Features in Adults with ADHD and Comorbid Anxiety Disorders at Psych Congress 2026
Fuente
Otsuka Pharmaceutical Co., Ltd.
Editor
Business Wire
1.00
0
03/08/2026
Otsuka Unveils Unprecedented Phase 3 VISIONARY Two-Year eGFR Results Demonstrating VOYXACT® (sibeprenlimab-szsi) Stabilizes Kidney Function Decline to Baseline Physiologic Rate, Fundamentally Altering Disease Progression in IgA Nephropathy (IgAN)
Fuente
Otsuka Pharmaceutical Co., Ltd.
Editor
Business Wire
1.00
0
25/07/2026
Biotecnología
Sanidad
Higiene alimentaria
Salud
Farmacéutica
Otsuka Receives FDA Approval for First-in-Class SIMTRIYO® (centanafadine) for the Treatment of Attention-Deficit Hyperactivity Disorder (ADHD) in Adults and Pediatric Patients Aged 6 Years and Older
Fuente
Otsuka Pharmaceutical Co., Ltd.
Editor
Business Wire
1.00
0
01/07/2026
Industria
Ciencia
Biotecnología
Farmacéutica
Sanidad
Salud
Higiene alimentaria
Medicina - Varios
Otsuka Reports Positive Phase 3 VISIONARY Two-Year eGFR Results Demonstrating VOYXACT® (sibeprenlimab-szsi) Prevented Progression to Kidney Failure and Improved Kidney Function in IgA Nephropathy (IgAN)
Fuente
Otsuka Pharmaceutical Co., Ltd.
Editor
Business Wire
1.00
0
25/06/2026
Industria
Psiquiatría
Higiene alimentaria
Salud
Medicina - Varios
Farmacéutica
Biotecnología
Otsuka Announces Positive Phase 3b Results for Centanafadine in Adults with ADHD and Comorbid Anxiety
Fuente
Otsuka Pharmaceutical Co., Ltd.
Editor
Business Wire
1.00
0
12/06/2026
Mercado de valores
Biotecnología
Sanidad
Psiquiatría
Salud
Farmacéutica
Otsuka Completes Acquisition of Transcend Therapeutics to Advance Next-Generation Neuropsychiatric Treatments
Fuente
Otsuka Pharmaceutical Co., Ltd.
Editor
Business Wire
1.00
0
04/06/2026
Otsuka Presents Positive Interim Phase 3 VISIONARY eGFR Data Showing VOYXACT® (sibeprenlimab-szsi) Preserved Kidney Function Over 12 Months in IgA Nephropathy (IgAN)
Fuente
Otsuka Pharmaceutical Co., Ltd.
Editor
Business Wire
1.00
0
28/05/2026
Ciencia
Biotecnología
Farmacéutica
Salud
Higiene alimentaria
Medicina - Varios
Eventos
Industria
Otsuka Presents New Phase 3 Post Hoc Analyses of Centanafadine Highlighting Improvement in Executive Function and Emotional Dysregulation in Adults with ADHD at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
Fuente
Otsuka Pharmaceutical Co., Ltd.
Editor
Business Wire
1.00
0
25/03/2026
Eventos
Industria
Sanidad
Higiene alimentaria
Salud
Farmacéutica
Medicina - Varios
Otsuka Showcases New Efficacy and Safety Data of VOYXACT® (sibeprenlimab-szsi) in Patients with IgA Nephropathy (IgAN) at the 2026 ISN World Congress of Nephrology Highlighting the Impact of APRIL Inhibition
Fuente
Otsuka Pharmaceutical Co., Ltd.
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0